v3.26.1
Acquisitions - Summary of Purchase Price Allocation (Details) - USD ($)
$ in Millions
Jun. 30, 2026
Dec. 31, 2025
Mar. 24, 2025
Jan. 16, 2025
Disclosure of detailed information about business combination [line items]        
Goodwill $ 9,259 $ 9,256    
Aurion Biotech, Inc.        
Disclosure of detailed information about business combination [line items]        
Property, plant and equipment     $ 3  
Right-of-use assets     6  
Deferred tax assets     40  
Other current assets     6  
Cash and cash equivalents     26  
Non-current lease liabilities     (4)  
Non-current financial debts     (1)  
Deferred tax liabilities     (202)  
Current financial debts     (34)  
Current lease liabilities     (2)  
Current income tax liabilities     (1)  
Trade payables     (3)  
Provisions and other current liabilities     (11)  
Net identifiable assets acquired     708  
Goodwill     175  
Non-controlling interests     (27)  
Net assets acquired as a result of business combination     856  
Cash paid at closing     522  
Previously-held investment in associated company     334  
Total acquisition date fair value of consideration     856  
Total acquisition date fair value of consideration     486  
Aurion Biotech, Inc. | Current marketed products        
Disclosure of detailed information about business combination [line items]        
Intangible assets     65  
Aurion Biotech, Inc. | Acquired IPR&D        
Disclosure of detailed information about business combination [line items]        
Intangible assets     $ 820  
Cylite Pty Ltd.        
Disclosure of detailed information about business combination [line items]        
Property, plant and equipment   1    
Right-of-use assets   1    
Inventories   1    
Cash and cash equivalents   6    
Other assets   1    
Deferred tax liabilities   (11)    
Lease liabilities   (1)    
Trade payables   (1)    
Provisions and other current liabilities   (1)    
Net identifiable assets acquired   33    
Goodwill   90   $ 90
Net assets acquired as a result of business combination   123    
Cash paid at closing   78    
Cash expected to be paid after closing   2    
Previously-held FVOCI financial investment   11    
Previously-held commercialization rights in intangible assets   9    
Contingent consideration   9    
Previously-held investment in associated company   14   $ 14
Total acquisition date fair value of consideration   123    
Cylite Pty Ltd. | Current marketed products        
Disclosure of detailed information about business combination [line items]        
Intangible assets   4    
Cylite Pty Ltd. | Acquired IPR&D        
Disclosure of detailed information about business combination [line items]        
Intangible assets   $ 33